Shared on03 Oct 25Fair value Increased 27%
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
Shared on24 Apr 25Fair value Decreased 14%
AnalystConsensusTarget has increased revenue growth from 198.4% to 228.1%, decreased profit margin from 17.3% to 15.6%, decreased future PE multiple from 156.7x to 95.5x and decreased shares outstanding growth rate from 0.1% to 0.0%.
Shared on17 Apr 25
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 140.4x to 156.7x.
Shared on09 Apr 25Fair value Increased 11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.